Progyny, Inc. (NASDAQ:PGNY) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• Analysts maintain a Moderate Buy consensus on Progyny, with nine buy ratings, three holds and one strong-buy rating. The average 12-month price target is $34.36, above the stock’s reported $27.13 price.
• Progyny reported quarterly EPS of $0.55, beating the $0.33 analyst consensus, while revenue rose 5.3% year over year to $350.51 million. Management issued Q3 and full-year 2026 EPS guidance.
• The company authorized a $200 million share-repurchase program, potentially covering up to 10.3% of outstanding shares; institutional investors own 94.93% of the stock.

Shares of Progyny, Inc. (NASDAQ:PGNY - Get Free Report) have received an average rating of "Moderate Buy" from the thirteen brokerages that are presently covering the stock, Marketbeat.com reports. Three research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $34.3636.

Several brokerages have issued reports on PGNY. Leerink Partners set a $38.00 price objective on shares of Progyny in a research note on Wednesday, July 22nd. Bank of America raised their target price on shares of Progyny from $29.00 to $31.00 and gave the stock a "buy" rating in a research note on Tuesday, June 2nd. Wall Street Zen upgraded shares of Progyny from a "buy" rating to a "strong-buy" rating in a research note on Saturday. Wells Fargo & Company began coverage on shares of Progyny in a report on Thursday, August 20th. They set an "overweight" rating and a $37.00 price target for the company. Finally, Zacks Research upgraded shares of Progyny from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, July 8th.

Insider Activity at Progyny

In other Progyny news, Director Kevin Gordon sold 11,500 shares of the business's stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $27.94, for a total transaction of $321,310.00. Following the sale, the director directly owned 6,792 shares in the company, valued at approximately $189,768.48. The trade was a 62.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 9.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Progyny

Several hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in shares of Progyny in the second quarter valued at about $334,426,000. Fort Washington Investment Advisors Inc. OH increased its position in Progyny by 46.9% during the 1st quarter. Fort Washington Investment Advisors Inc. OH now owns 2,693,393 shares of the company's stock worth $45,734,000 after purchasing an additional 859,289 shares in the last quarter. Bank of America Corp DE acquired a new position in shares of Progyny in the second quarter valued at approximately $17,264,000. William Blair Investment Management LLC purchased a new stake in Progyny in the 2nd quarter worth approximately $16,807,000. Finally, Danske Bank A S acquired a new position in Progyny in the 2nd quarter valued at $15,243,000. 94.93% of the stock is owned by institutional investors and hedge funds.

Progyny Stock Performance

Progyny stock opened at $27.13 on Monday. The stock has a 50 day moving average of $28.37 and a two-hundred day moving average of $24.30. Progyny has a twelve month low of $16.10 and a twelve month high of $33.06. The stock has a market capitalization of $2.08 billion, a price-to-earnings ratio of 29.49, a PEG ratio of 1.87 and a beta of 0.99.

Progyny (NASDAQ:PGNY - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported $0.55 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.33 by $0.22. Progyny had a return on equity of 15.98% and a net margin of 6.00%.The business had revenue of $350.51 million for the quarter, compared to analyst estimates of $349.05 million. During the same quarter in the previous year, the company posted $0.19 earnings per share. The company's revenue for the quarter was up 5.3% compared to the same quarter last year. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. Equities analysts predict that Progyny will post 1.25 earnings per share for the current year.

Progyny declared that its Board of Directors has initiated a share repurchase program on Tuesday, May 26th that allows the company to buyback $200.00 million in shares. This buyback authorization allows the company to repurchase up to 10.3% of its shares through open market purchases. Shares buyback programs are often an indication that the company's management believes its stock is undervalued.

About Progyny

Progyny, Inc is a benefits management company that provides fertility and family-building solutions to employers and their employees. Its platform is designed to support individuals and couples pursuing fertility treatment, including in vitro fertilization, egg freezing, donor services, gestational surrogacy and adoption.

The company's services combine access to a network of fertility specialists with personalized guidance, care coordination and treatment support. Progyny also offers pharmacy benefits through Progyny Rx, helping members obtain and manage medications commonly used in fertility treatments.

Progyny primarily serves employer-sponsored benefit programs in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.